AIRLINK 72.13 Increased By ▲ 2.93 (4.23%)
BOP 5.04 Increased By ▲ 0.14 (2.86%)
CNERGY 4.32 Increased By ▲ 0.06 (1.41%)
DFML 31.40 Increased By ▲ 0.15 (0.48%)
DGKC 80.37 Increased By ▲ 3.12 (4.04%)
FCCL 21.03 Increased By ▲ 1.03 (5.15%)
FFBL 34.82 Decreased By ▼ -0.18 (-0.51%)
FFL 9.17 Increased By ▲ 0.05 (0.55%)
GGL 9.81 Increased By ▲ 0.01 (0.1%)
HBL 113.40 Increased By ▲ 0.64 (0.57%)
HUBC 134.20 Increased By ▲ 1.16 (0.87%)
HUMNL 7.02 Increased By ▲ 0.07 (1.01%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.20 Increased By ▲ 0.60 (1.64%)
OGDC 135.40 Increased By ▲ 2.53 (1.9%)
PAEL 23.69 Increased By ▲ 1.05 (4.64%)
PIAA 24.60 Increased By ▲ 0.40 (1.65%)
PIBTL 6.52 Increased By ▲ 0.06 (0.93%)
PPL 120.40 Increased By ▲ 4.10 (3.53%)
PRL 26.33 Increased By ▲ 0.43 (1.66%)
PTC 13.20 Increased By ▲ 0.12 (0.92%)
SEARL 52.40 Increased By ▲ 0.40 (0.77%)
SNGP 71.40 Increased By ▲ 3.80 (5.62%)
SSGC 10.60 Increased By ▲ 0.06 (0.57%)
TELE 8.40 Increased By ▲ 0.12 (1.45%)
TPLP 11.11 Increased By ▲ 0.31 (2.87%)
TRG 60.51 Increased By ▲ 1.22 (2.06%)
UNITY 25.21 Increased By ▲ 0.08 (0.32%)
WTL 1.27 No Change ▼ 0.00 (0%)
BR100 7,490 Increased By 81.2 (1.1%)
BR30 24,512 Increased By 475.5 (1.98%)
KSE100 71,505 Increased By 838.4 (1.19%)
KSE30 23,444 Increased By 220 (0.95%)

LAHORE: Getz Pharma manufactures safe and efficacious medicines in its WHO, PIC/s, and EAEU pre-qualified manufacturing facility, a spokesman of the company, said.

Responding to false information about its product Risek IV 40 mg injection on electronic and social media, the spokesman said. “On February 12, 2024, the Federal Inspector of Drugs-IV, while conducting market surveillance in Moro, Sindh, identified counterfeit Risek 40mg IV injections at the premises of M/s Qalanari Medicos on Hospital Road, Moro, Nowsheroferoz.

Samples were sent for testing, including confirmation by Getz Pharma. We confirmed the sample as counterfeit, not manufactured by us, and provided a comparative analysis report to authorities, urging action.”

Getz Pharma condemns the misreporting by the electronic media of the Alert issued by Drug Regulatory Authority of Pakistan (DRAP) as if our manufactured product was deemed spurious or counterfeit, requiring recall.

Copyright Business Recorder, 2024

Comments

Comments are closed.